Vasculitis in Adults and Children: Symptoms, Diagnosis and Treatment—2nd Edition

Dear Colleagues,

We are pleased to announce the second edition of the Special Issue “Vasculitis in Adults and Children: Symptoms, Diagnosis and Treatment”, which comes as a result of the success of the first edition, in which we published six papers.

Vasculitis is classified into large-vessel, medium-vessel and small-vessel vasculitis according to the size of the affected arteries and causes serious organ damage through ischemia, infarction, bleeding, dissection and aneurysm formation. Treatment previously relied on high-dose glucocorticoids and cyclophosphamide, regardless of the size of the affected arteries, with substantial side effects; however, in recent years, molecularly targeted therapeutic agents, such as tocilizumab, rituximab, mepolizumab and avacopan, have enabled remission to be effectively induced and/or maintained and have also reduced the total amount of glucocorticoids required for the corresponding vasculitis. This Special Issue, “Vasculitis in Adults and Children: Symptoms, Diagnosis and Treatment”, will summarize recent discoveries regarding the symptoms, diagnosis and treatment of vasculitis in both adults and children. Clinical research studies regarding epidemiology, gender difference, prognostic factors, complications, classification criteria and treatment, as well as basic/translational research that tries to identify novel therapeutic targets, are welcome. Through these contributions, we will be able to better understand how to diagnose and treat vasculitis. We will also discuss how future therapeutic strategies could resolve currently unmet medical needs. Thus, authors are encouraged to submit original research, review articles, systematic reviews and meta-analyses.

Dr. Ryu Watanabe
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• vasculitis
• glucocorticoids
• cyclophosphamide
• molecularly targeted therapy
• unmet clinical needs
• potential therapeutic targets

• Vasculitis in Adults and Children: Symptoms, Diagnosis and Treatment in Journal of Clinical Medicine (6 articles)